Account
Inquiry
Tirzepatide (LY3298176) is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed for type 2 diabetes treatment. This pharmaceutical grade compound demonstrates superior efficacy in both glucose regulation and weight reduction compared to selective GLP-1 receptor agonists.
The molecular structure of Tirzepatide features a lysine side chain with PEG modification, enhancing water solubility while maintaining biological activity. Clinical studies indicate significant weight loss results, with SURMOUNT-1 trial participants achieving 15-20.9% reduction after 72 weeks of treatment.
As a once-weekly administered peptide, Tirzepatide combines the therapeutic benefits of two incretin hormones into a single molecule. Its mechanism of action involves binding to both GIP and GLP-1 receptors, with greater affinity for GIP receptors, resulting in enhanced glucose control.
Current research focuses on Tirzepatide's potential applications in obesity treatment, with FDA Fast Track designation granted for weight management in overweight adults with related health conditions. The compound represents a significant advancement in metabolic disorder therapeutics.
For researchers seeking to buy Tirzepatide, we offer pharmaceutical grade material with comprehensive analytical documentation. Our production follows strict quality protocols to ensure batch-to-batch consistency and purity.
